Tech Company Financing Transactions
AnBogen Therapeutics Funding Round
On 2/1/2024, AnBogen Therapeutics received $12.5 million in Series A funding from CDIB Capital Group, Maxpro Ventures and National Development Fund of Taiwan.
Transaction Overview
Company Name
Announced On
2/1/2024
Transaction Type
Venture Equity
Amount
$12,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development its two main drug candidates, ABT-101 and ABT-301.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
No.99, Lane 130, Sec. 1, Research Institute Road, Nangang Di C523
Taipei, 11571
Taiwan
Taipei, 11571
Taiwan
Phone
Website
Email Address
Overview
Anbogen Therapeutics is a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients. Founded by a group of exceptional scientists from National Health Research Institute, the most prestigious medical research institute in Taiwan, we are devoted to bringing the gap between research and clinical development and dedicated to creating breakthrough science that changes the life of cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tsu-An Hsu
President
Joe Hsueh
VP - Bus. Development
Chun-Hsuan Lo
VP - Bus. Development
Kien-Thiam Tan
VP - Bus. Development
Angus Tsung-Kai Wu
VP - Finance
Endy Yang
Browse more venture capital transactions:
Prev: 2/1/2024: LimmaTech Biologics venture capital transaction
Next: 2/1/2024: Watershed venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs